ANI Pharma Inc (ANIP) 59.86 $ANIP Mylan (MYL) G
Post# of 273258
Posted On: 09/02/2016 11:13:05 PM
ANI Pharma Inc (ANIP) 59.86 $ANIP
Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)
Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 43.27 (+0.10), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), ARNA: 1.57 (+0.01)
Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Roche Immuno-oncology Drug Tecentriq Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:22AM CDT
Roche (RHHBY) announced positive results from a phase III study, OAK, on its immuno-oncology drug, Tecentriq.
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)
What Makes Editas Medicine (EDIT) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:14AM CDT
One stock that you may want to consider dropping is Editas Medicine Inc. (EDIT), which has witnessed a significant price decline in the past four weeks
EDIT: 16.11 (-0.63), ANIP: 59.86 (-1.56)
Pfizer's Lung Cancer Drug Xalkori Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:42AM CDT
Pfizer, Inc. (PFE) announced that its lung cancer drug Xalkori has been approved for an additional indication by the European Commission (EC).
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09)
Array (ARRY) Presents Positive Cardiovascular Trial Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 10:28AM CDT
Array BioPharma (ARRY) presented positive results from a phase II study on its pipeline candidate, ARRY-797, at the European Society of Cardiology Congress 2016 in Rome, Italy.
ANIP: 59.86 (-1.56), AZN: 33.31 (+0.71), ARRY: 3.50 (-0.02)
Express Scripts' New Program to Lower Diabetes Care Costs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:00AM CDT
Express Scripts Holding Company (ESRX) has launched the Diabetes Care Value Program to lower costs for patients and provide better care.
ESRX: 72.54 (+0.32), ANIP: 59.86 (-1.56), LLY: 76.85 (-0.38)
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09), ARIA: 10.12 (-0.07)
Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.86 (-0.06), VRX: 28.76 (-0.36), ANIP: 59.86 (-1.56), PCRX: 39.04 (-1.33)
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)
CoLucid Pharmaceuticals (CLCD) Jumps: Stock Rises 12.1%
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:15AM CDT
CoLucid Pharmaceuticals, Inc. (CLCD) shares rose over 12% in the last trading session.
CLCD: 10.66 (+0.41), ANIP: 59.86 (-1.56)
This Week's Hidden Gems: (AMWD)(ANIP)
Tracey Ryniec - Zacks Investment Research - Tue Aug 30, 2:03PM CDT
These 2 companies are crushing it. Tracey discusses how they???re doing it.
ANIP: 59.86 (-1.56), AMWD: 87.77 (+1.21)
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 59.86 (-1.56), INCY: 82.02 (+1.21), CTIC: 0.39 (unch), ANIK: 47.89 (-0.05)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ALXN: 123.67 (-1.96), ANIK: 47.89 (-0.05)
Amgen (AMGN) Reports Positive Data on Prolia and Repatha
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:03AM CDT
Amgen announced positive data on Prolia and Repatha from late stage studies.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Inovio Stock Up as Second Zika Virus Vaccine Study Begins
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:07AM CDT
Inovio Pharmaceuticals' (INO) shares were up after the company started a second study evaluating its preventive Zika vaccine, GLS-5700, in Puerto Rico.
INO: 9.08 (-0.06), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), XON: 25.33 (+0.04)
Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 59.86 (-1.56), MCUR: 1.58 (-0.07), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
Mylan (MYL) Gets Positive Copaxone USPTO Ruling Yet Again
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:07AM CDT
Mylan (MYL) reported that the U.S. Patent and Trademark Office has invalidated the third patent covering Copaxone (40 mg/mL) via inter partes review proceeding.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32)
Arena (ARNA) Beacon Discovery to Boost Research Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 9:06AM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced the formation of Beacon Discovery Inc., a private drug discovery enterprise to develop compounds that can be used for drug discovery and early-stage development.
CBM: 43.27 (+0.10), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), ARNA: 1.57 (+0.01)
Amgen Gets FDA Approval for Label Expansion of Blincyto
Zacks Equity Research - Zacks Investment Research - Fri Sep 02, 7:45AM CDT
Amgen, Inc. (AMGN) announced that the FDA has approved a label expansion for its leukemia immunotherapy Blincyto.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Roche Immuno-oncology Drug Tecentriq Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:22AM CDT
Roche (RHHBY) announced positive results from a phase III study, OAK, on its immuno-oncology drug, Tecentriq.
ANIP: 59.86 (-1.56), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Amarin (AMRN) Ends Patient Randomization in Vascepa Study
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:20AM CDT
Amarin (AMRN) announced that it has finished randomizing patients in the phase III REDUCE-IT study on Vascepa (icosapent ethyl).
ANIP: 59.86 (-1.56), AMRN: 2.92 (+0.13), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33)
What Makes Editas Medicine (EDIT) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:14AM CDT
One stock that you may want to consider dropping is Editas Medicine Inc. (EDIT), which has witnessed a significant price decline in the past four weeks
EDIT: 16.11 (-0.63), ANIP: 59.86 (-1.56)
Pfizer's Lung Cancer Drug Xalkori Label Expanded in the EU
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:42AM CDT
Pfizer, Inc. (PFE) announced that its lung cancer drug Xalkori has been approved for an additional indication by the European Commission (EC).
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09)
Array (ARRY) Presents Positive Cardiovascular Trial Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 10:28AM CDT
Array BioPharma (ARRY) presented positive results from a phase II study on its pipeline candidate, ARRY-797, at the European Society of Cardiology Congress 2016 in Rome, Italy.
ANIP: 59.86 (-1.56), AZN: 33.31 (+0.71), ARRY: 3.50 (-0.02)
Express Scripts' New Program to Lower Diabetes Care Costs
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 9:00AM CDT
Express Scripts Holding Company (ESRX) has launched the Diabetes Care Value Program to lower costs for patients and provide better care.
ESRX: 72.54 (+0.32), ANIP: 59.86 (-1.56), LLY: 76.85 (-0.38)
ARIAD Finishes Rolling NDA for Lung Cancer Drug Brigatinib
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:24AM CDT
ARIAD Pharmaceuticals (ARIA) completed the rolling submission of the new drug application for brigatinib, to the FDA.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), PFE: 34.77 (+0.09), ARIA: 10.12 (-0.07)
Orexigen Stock Up on Commercialization Deal for Contrave
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 8:11AM CDT
Orexigen (OREX) announced that it has entered into a commercialization and distributorship agreement with Valeant Canada for Contrave in Canada.
OREX: 3.86 (-0.06), VRX: 28.76 (-0.36), ANIP: 59.86 (-1.56), PCRX: 39.04 (-1.33)
Rigel (RIGL) Stock Up on Positive Phase III Fostamatinib Data
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:16AM CDT
Rigel (RIGL) announced positive data from a phase III study on fostamatinib for the treatment of adult chronic/persistent ITP.
ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05), PCRX: 39.04 (-1.33), RIGL: 3.40 (-0.05)
CoLucid Pharmaceuticals (CLCD) Jumps: Stock Rises 12.1%
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 7:15AM CDT
CoLucid Pharmaceuticals, Inc. (CLCD) shares rose over 12% in the last trading session.
CLCD: 10.66 (+0.41), ANIP: 59.86 (-1.56)
This Week's Hidden Gems: (AMWD)(ANIP)
Tracey Ryniec - Zacks Investment Research - Tue Aug 30, 2:03PM CDT
These 2 companies are crushing it. Tracey discusses how they???re doing it.
ANIP: 59.86 (-1.56), AMWD: 87.77 (+1.21)
CTI BioPharma Reports Mixed Pacritinib Study Data, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:05AM CDT
CTI BioPharma (CTIC) announced top-line results from a phase III study (PERSIST-2) on pacritinib for the treatment of myelofibrosis.
ANIP: 59.86 (-1.56), INCY: 82.02 (+1.21), CTIC: 0.39 (unch), ANIK: 47.89 (-0.05)
Alexion's GVHD Candidate Gets Orphan Drug Status in the EU
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:04AM CDT
Alexion Pharmaceuticals' (ALXN) ALXN1007 received orphan drug designation in the EU for the treatment of graft-versus-host disease.
ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), ALXN: 123.67 (-1.96), ANIK: 47.89 (-0.05)
Amgen (AMGN) Reports Positive Data on Prolia and Repatha
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 9:03AM CDT
Amgen announced positive data on Prolia and Repatha from late stage studies.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), ANIK: 47.89 (-0.05)
Inovio Stock Up as Second Zika Virus Vaccine Study Begins
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:07AM CDT
Inovio Pharmaceuticals' (INO) shares were up after the company started a second study evaluating its preventive Zika vaccine, GLS-5700, in Puerto Rico.
INO: 9.08 (-0.06), ANIP: 59.86 (-1.56), GERN: 2.75 (+0.02), XON: 25.33 (+0.04)
Macrocure Stock Up on Merger Deal with Leap Therapeutics
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:05AM CDT
Macrocure Ltd. (MCUR) announced that it has signed a definitive merger agreement with the privately held company, Leap Therapeutics, Inc.
ANIP: 59.86 (-1.56), MCUR: 1.58 (-0.07), LLY: 76.85 (-0.38), ANIK: 47.89 (-0.05)
Regeneron/Sanofi Present Positive Phase III Praluent Data
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:33AM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
ANIP: 59.86 (-1.56), AMGN: 169.77 (-0.36), SNY: 39.18 (+0.77), REGN: 388.64 (-4.76)
(0)
(0)Scroll down for more posts ▼